Drug Trial Radar · NCT03829436
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Mar 20, 2019
Primary completion
Sep 7, 2022
Study completion Sep 7, 2022
Sponsor
- Lead sponsor
- Tempest TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.
Conditions
- Hepatocellular Carcinoma
- Metastatic Castration Resistant Prostate Cancer
- Renal Cell Carcinoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Squamous Cell Carcinoma of Head and Neck
- Triple-Negative Breast Cancer
- Urothelial Carcinoma
- Cholangiocarcinoma
- GastroEsophageal Cancer
- Pancreatic Cancer
- Sarcoma
Interventions
Part 1 TPST-1120Drug
Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
Part 2 TPST-1120 + nivolumabDrug
Subjects will receive escalating doses of TPST-1120 administered orally twice daily
Part 3 TPST-1120Drug
Selected dose of TPST-1120 administered orally twice daily until disease progression
Part 4 TPST-1120 + nivolumabDrug
Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.Time frame: From start of treatment to end of treatment, up to 36 months
- Incidence of treatment-emergent adverse events as assessed by NCI-CTCAE v5.0 of TPST-1120 as a single agent and in combination with nivolumab.Time frame: From start of treatment to end of treatment, up to 36 months
- Identify the maximum tolerated doseTime frame: From start of treatment to end of treatment, up to 36 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
University of California - San Francisco
San Francisco, California
Miami Cancer Institute
Miami, Florida
Johns Hopkins University
Baltimore, Maryland
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Columbia University Medical Center
New York, New York
Carolina BioOncology Institute
Huntersville, North Carolina
Stephenson Cancer Center
Oklahoma City, Oklahoma
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute - TN
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.